



taken orally by patients
with lung cancer in a
phase I trial
C. F. A1brecht, P. B. Kruger, B. J. Smit, M. Freestone,
L. Gouws, R. Miller, P. P. van Jaarsveld
Objective. To study the pharmacokinetic behaviour of
hypoxoside taken orally by 24 patients with lung cancer.
Design. Randomised open study with three single doses
of 1 600, 2 400 and 3 200 mg standardised Hypoxis plant
extract (200 mg capsules) and a multiple-dose study on
the first 6 patients taking 4 capsules 3 times daily for 11
days.
Participants and setting. Patients with histologically
proven squamous, large-cell or adenocarcinoma were
hospitalised at the Radiation Oncology Ward, Karl Bremer
Hospital, Bellville, W. Cape.
Methods. Blood was drawn at regular intervals up to 75
hours after single doses and the concentrations of
metabolites of the aglucone of hypoxoside, rooperol, were
measured with a high-performance liquid chromatography .
method. For the multiple-dose study blood was drawn
before the first dose each day. Concentration-time
relationships were analysed according to a conventional
single open-compartment model and also by using the
NONMEM digital computer programme.
Results. Neither hypoxoside nor rooperol appear in
circulation. This is due to complete phase 11
biotransformation to diglucuronide, disulphate and mixed
glucuronide-sulphate metabolites, of which the latter is the
major component. Considerable interpatient variation in
concentration-time relationships was found in the single-
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dose studies. It was due to an active enterohepatic
recirculation in some patients and a distinct lag phase in
others together with zero-order rate of formation of
rooperol in the colon. Computer modelling indicated a
single open-compartment model in which the mass of the
patient did not influence volume of distribution and
clearance because formation of the metabolites is
dependent on the metabolising capacity of the patient.
However, the elimination of the metabolites follows first-
order kinetics with half-lives ranging from 50 hours for the
major metabolite to 20 hours for the two minor
metabolites. Multiple-dose studies also showed large
interpatient variation.
Conclusion. In order to reach metabolite levels near
100 ~g/ml, which have been shown to be tumouricidal
after enzymatic deconjugation to rooperol, maintenance
doses need to be individualised for each patient. For
most patients, however, a daily dose of 2 400 mg was
sufficient.
S Atr Med J 1995; 85: 861-865.
Hypoxoside is the major diglucoside found in extracts of
the corms of several Hypoxis species. ' -4 Historical and
anecdotal cases of cancer cure by drinking extracts of
Hypoxis led to a recognised claim for its value as an
anticancer remedy. 5
In vitro hypoxoside has been shown to be non-toxic to
cancer cells at concentrations up to 100 ~g/mI.6.7 However,
when it is hydrolysed to its aglucone, rooperol, by [3-
glucosidase, cytotoxicity is found at concentrations ranging
from 2 to 10 ~g/mI.6.7 This action may be related to the
formation of reactive semiquinones and quinones which are
known to occur with dicatechols such as the closely related
cytotoxic agent, nor-dihydroguaiaretic acid."
In vivo hypoxoside has remarkable pharmacokinetic
properties. After oral ingestion the parent drug is not found
in the circulation. Only phase 11 metabolites (glucuronides
and sulphates) of rooperol are found which are also non-
toxic in tissue culture experiments!·6 Furthermore, a very
distinct species difference is present in so far as the
rooperol metabolites are found in the bile only of
experimental animals such as the mouse, rat and dog, while
they appear in the serum of man and the baboon.4,6
We obtained permission from our Ethics Committee and
the South African Medicines Control Council to conduct a
phase I pharmacokinetic and toxicity trial with 24 lung
cancer patients for whom no alternative therapy was
available, based on the arguments that: (I) the
pharmacokinetic properties of hypoxoside preclude its use
in rodent models for in vivo anticancer studies; (il) several
lung cancer cell lines are extremely sensitive to rooperol;6
and (iil) rooperol is not a mutagen in the Ames test (to be
published elsewhere). ,
In this report we document the pharmacokinetic
properties of the metabolites when hypoxoside is taken
orally by humans.
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Material and methods ophthalmoscopy and audiometry as well as full
haematological and biochemical investigations.
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Fig. 1. HPLC of standardised Hypoxis extract. Hypoxoside with
Rt =8,2 minutes is the major component with traces of
dehydroxy- and bis-dehydroxy-hypoxoside present (Rt = 8,5 and
8,7 minutes, respectively).
Patient eligibility
Patients had to be above 21 years of age with histologically
proven squamous cell, large-cell or adenocarcinoma of the
bronchus. Informed consent according to the Declaration of
Helsinki was required from each patient. Exclusion criteria
included impaired renal, hepatic or cardiac function,
concomitant anticancer therapy, inadequate performance
status (H2 or lower), and patients who, in the opinion of the
investigator, had less than 3 months to live.
Fig. 2 shows a high-performance liquid chromatogram of the
serum of a patient taking hypoxoside orally. It was shown by
Analyses and pharmacokinetic
calculations
Hypoxoside metabolite concentrations were measured by
high-performance liquid chromatography (HPLC) according
to the method of Kruger et al. 9 For pharmacokinetic
calculations a single open-compartment model'o was used
initially to fit concentration-time data of the metabolites as
they became available. The single-dose data were analysed
after completion of the trial by using the digital computer
programme NONMEM (version 2, level 1, double precision)."
Estimates were obtained for: (I) the population means of
pharmacokinetic parameters assuming a one- or two-
compartment open model with first-order absorption.; (iJ)
variance of the population means; (iit) variance of th.~
residual random error; (iv) standard errors of the parameter
estimates; (v) correlation matrix of the estimates; ang, (VI)
value of the objective function, which is equal to mi~us
twice the log-likelihood of the data. .
Intersubject variability in clearance (Cl) and volume of
distribution M, as well as residual intrasubject error, were
modelled with additive (homoscedastic) error models. As an
example the one-compartment open-model parameters are
depicted below; however, the same principle applies to the
more complex models.
Cl, = Cl + njC1
Vd, =V + n,Vd
ka. =ka + n,ka
Cij = CM', + Eij'
where q, Vj and ka. are the- pharmacokinetic parameters for
the individual as predicted by the regression model, Cl, V
and ka are the population means of clearance, volume and
absorption rate constant, njC', njVand ni" are randomly
distributed terms with zero mean and variances wc,, Wv and
wka' respectively, that distinguish the jth individual's Cl, V and
ka from those predicted by the regression model, C" is the
ith observed concentration for the jth individual, and CM" is
the ith observed concentration predicted by the model for
the jth individual. This value includes the contribution of the
n,c" r1;v~ and nj
ka terms. E, is the residual intrasubject error
term, representing randomly distributed statistical errors with
mean zero and variance if.
The significance of various factors that influence the
pharmacokinetic parameters was tested by noting the
difference in the objective-function values (DOBF) obtained
from the evaluation of the full model and restricted model
(one or more parameters fixed). The difference in the
objective function values obtained for the general and
restricted models is approximately chi-square-distributed
with degrees of freedom equal to the number of fixed
parameters in the restricted model.'2 A DOSF of 3,8 for 1














Hypoxoside was supplied by Essential Sterolin Products in
capsule form, each capsule containing 200 mg of
standardised plant extract. Fig. 1 shows a high-performance
liquid chromatogram of the contents of a capsule which
illustrates the elution profile of hypoxoside as described by
Kruger et al.' Routine HPLC analyses assured uniform
quality of each batch of plant extract within the following
limits: 50 - 55% hypoxoside, 8 - 12% f3-sitosterol and
0,2 - 0,3% l3-sitosterol glucoside. The remaining 33 - 42%
of the extract, not detectable by the HPLC system,
consisted largely of complex carbohydrates with traces of
reducing sugars, amino acids, tannins and flavonoids. Tests





The approved protocol included a randomised, open, single-
dose study with three dosage levels (8, 12 and 16 capsules)
administered to three groups of the 24 patients. The first
group of 6 patients who entered the trial also participated in
a controlled multiple-dose study for 11 days.
Patients were hospitalised in the Radiation Oncology
Ward, Karl Sremer Hospital, Sellville, W. Cape for the single-
and multiple-dose studies. Upon admission the medical
histories of all patients were recorded and they underwent
thorough baseline physical examinations which included full
neurological and cardiological examinations,






Fig. 2. HPLC of the metabolites of hypoxoside present in the
serum of a patient. Metabolite A (Rt = 7,6 minI is the
diglucuronide of rooperol; metabolite B (Rt = 8,4 minI the mixed







compartment 0/J and intercompartmental clearance (Q2J.
Differences are assumed to be due to random inter- and
intrasubject variation. Results are also presented in Table I.
In spite of the increased number of parameters the fit of the
two-compartment model to the data is significantly worse
than the one-compartment model, since the difference in
objective function (OBJ) is 7,4. Model 1 is therefore
considered appropriate in further model building.
Model 3 in Table I incorporates mass as a function of
clearance. The increase in the objective function of 78
indicates that it is not appropriate to express clearance
proportional to mass for this metabolite. Model 4 includes
mass in volume of distribution which resulted in an increase
of 49,4 in the objective function and is therefore not
appropriate.
Fig. 3. Concentration-time relationships of the major metabolite
(see Fig. 2) in the serum of three groups of patients who took



































Kruger et al.' that the major metabolite B with Rt =8,4
minutes is a mixed glucuronide-sulphate conjugate of
rooperol. The two minor metabolites A (Rt = 7,6 minutes)
and C (Rt = 9,6 minutes) are the diglucuronide and
disulphate conjugates, respectively.
The concentration-time relationship of the major
metabolite B, studied in groups of 7,7 and 6 patients who
received single doses of 1 600, 2 400 and 3 200 mg of
standardised plant extract respectively, is shown in Fig. 3.
It is clear that a relatively large interpatient variation exists.
This is understood in terms of the fact that the concentration
of metabolites in the serum obviously depends both on the
rates of deconjugation of hypoxoside and on the
conjugation of rooperol. Furthermore, an enterohepa:tic
recirculation is evident in some patients where the initial
rapid rise in concentration of metabolite B is followed by a
drop and a further rise in concentration during the first 15
hours after ingestion. In some patients a distinct lag phase
is present before appearance of metabolite B. Calculations
of the average area under the curve (AUC) of the
concentration-time relationships revealed that it is not
linearly related to dose. If the average AUC of the 1 600 mg
dose is taken as one, relative values of 0,86 and 1,55 are
obtained for the 2 400 and 3 200 mg doses respectively.
This implies that formation of rooperol, and possibly its
absorption, is a zero order saturable process. Consequently
escalating doses usually given in phase I trials in order to
reach toxic blood levels were not applicable in this study.
The data shown in Fig. 3 were subjected to NONMEM
analyses in a stepwise fashion to fit the following models:
A one-compartment open model (model 1) assuming that
all patients have the same clearance (Cl), volume of
distribution (V), rate of absorption (ka) and absorption lag
time (Tlag). Differences are assumed to be due to random
inter- and intrasubject variation. Iterative estimates of the'
fixed effects parameters with residual interindividual
variance (w) and 'residual intrasubject error variance (a2) are
presented in Table I.
Model 2 is a two-compartment open model which
assumes that all patients have the same Cl, ka, Tlag, volume
of the central compartment 0/,), volume of the peripheral
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Table I. Pharmacokinetic parameters of the major metabolite (8 in
Fig. 2) of hypoxoside obtained from NONMEM analyses of single-
dose data (see Fig. 3) .
Model
Parameter 2 3 4
T1ag (h) 0,995 0,586 1,31 0,207
ka (h-') 0,401 0,301 0,401 0,104
Cl (I/h) 4,39 0,317 0,372 x mass 0,341
+ 1,83
V, (I) 308 258 300 3,98 x mass
+ 394
Fig. 4 (upper part) shows that with mUltiple dosing of
hypoxoside (steady state), metabolites A and C reach an
average of 20% each of the serum concentration of B. This
is in agreement with first-order elimination of all the
metabolites and the half-life of B of 50,52 ± 15,77 hours in
comparison to that of A and C of 20,42 ± 6,15 and 20,14 ±
5,04 hours, respectively. Also shown in Fig. 4 (lower part) is
the variation in concentrations of metabolite B in 6 patients
who received 2 400 mg of hypoxoside daily divided into
three equal doses. The therapy was interrupted on day 9
(216 hours) which resulted in the decline in concentration of
metabolite B as shown in Fig. 4.
Discussion
When the pharmacodynamic and pharmacokinetic ~
properties ofhypoxoside were investigated by us4·ifit
became clear that its possible application as a pro'drug in
cancer therapy needed to be investigated further. Pj!rt of the
phase I study undertaken was to assess the ;
pharmacokinetic behaviour of the phase 11 metabolites since
no hypoxoside or rooperol appear in the blood. Only the
phase II metabolites can be measured, of which the mixed
glucuronide-sulphate is the major component. The
diglucuronide and disulphate metaboJites appear in the
blood at steady state as minor.metabolites (approximately
20% of the major metabolite) because their half-lives are
only 20 hours in comparison with the 50 hours of the major
metabolite.
It was possible to fit the concentration-time relationship of
the major metabolite to the simplest model, i.e. a single
open-compartment model which provided reasonable
estimates of the different pharmacokinetic parameters
(Table I, model 1). It must be kept in mind that for calculation
of clearance and volume of distribution a bio-availability
factor is needed which can only be determined after
intravenous administration of the compounds in question.
The finding that there is no relationship between clearance,
volume of distribution and mass of the patient (Table I,
models 3 and 4), however, justifies the indirect method of
analysing the data. It is also understandable that mass
should not play a significant role since the extent of
conversion of hypoxoside to rooperol, and in. turn, rooperol
to phase 11 metabolites, is obviously more dependent on the
metabolising activity of the gastro-intestinal system
(particularly the colon) an9 the liver of the patient rather than
the mass of the patient. The rather large interpatient
variation observed both with single':dose and multiple-dose
therapy (Figs 3 and 4) is probably also allied to the
metabolising capacity of the patient. This includes a lag
phase for appearance of the metabolites in the blood which
has a coefficient of variation of 225% (Table I). Some
patients also clearly showed active enterohepatic
recirculation of the metabolites shortly after hypoxoside was
ingested (Fig. 3).
Because of the relatively large interpatient variation, and
the zero-order formation of metabolites but predictable first-
order elimination kinetics, the long-term maintenance doses
of patients were adjusted in the toxicity study when

















w"., (h)' 5,38 7,26 4,85 191
wka(h)' 0,306 0,181 0,219 0,308
Wo (I/h)' 1,55 1,04 0,00024 0,0087 .
wV, (I)' 6,39 x 10' 6,5 x 10' 5,1x10' 3,7x 10'
<f (~g/ml)' 3,11 3,16 4,72 4,18
OBJ 794,4 801,8 872,4 843,8
• Not included.
30 --------------- ----------------------------












Fig. 4. Concentration-time relationships of metabolites in the
serum of patients who ingested 2 400 mg of standardised plant
extract daily. Three equal doses were taken and blood was drawn
before the first dose each day. The upper part shows the
concentrations of each of the three metabolites A, 8 and C (see
Fig. 2) in one patient while the lower part shows the
concentrations of metabolite 8 in 6 patients. The therapy was
stopped after 216 hours in 5 patients and after 192 hours in 1
patient. The latter patient was not available to follow the
decrease in concentration of metabolite 8 with time.
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metabolite serum concentrations in order to maintain a
steady-state concentration near 100 ~g/ml. Based on in vitro
experiments' the latter was considered adequate for
formation of tumouricidal rooperol concentrations. For most
patients a daily dose of 2 400 mg (4 capsules 3 times a day)
was sufficient.
This study was initiated and sponsored by Essential Sterolin
Products according to an agreement entered into with the
University of Stellenbosch.
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A phase I trial of hypoxoside
as an oral prodrug for
cancer therapy - absence
of toxicity
B. J. Smit, C. F. A1brecht, R. W. Liebenberg,
P. B. Kruger, M. Freestone, L. Gouws, E. Theron,
P. J. D. Bouic, 5. Etsebeth, P. P. van Jaarsveld
Objective. To assess the toxicity of hypoxoside taken
orally by 24 patients with lung cancer.
Design. Open study with patients taking 1 200 - 3 200
mg standardised Hypoxis plant extract (200 mg capsules)
per day divided in 3 doses in order to maintain metabolite
blood levels near 100 ~g/ml.
Participants and setting. Patients with histologically
proven squamous, large-cell or adenocarcinoma were
hospitalised initially at the radiation oncology ward, Kart
Bremer Hospital, Bellville, W. Cape. Thereafter they
returned every 2 weeks for full clinical examinations.
Methods. Routine biochemical and haematological
measurements were done. Patients underwent regular full
clinical examinations including radiographs and computed
tomography scanning according to the discretion of the
principal investigator.
Results. Nineteen patients on hypoxoside therapy
survived for an average of 4 months with progression of
their primary tumours and metastases, while 5 survived for
more than a year. One of them survived for 5 years and
histological examination of the primary lesion showed
absence of cancer. No toxic effects, in clinical
examinations or biochemical or haematological
measurements, were found that could be ascribed to the
ingestion of hypoxoside. Only one occasion of possible
drug intolerance, with anxiety, nausea, vomiting and
diarrhoea, was noted.
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